Skip to content
Open access

Enhancing Adeno-Associated Virus 2 Capsid Engineering Through Co-Evolutionary Coupling.

Aug 2026 · Biotechnology and Bioengineering · 0 citations · 45 references
Medicine

TL;DR

This study highlights the potential of using evolutionary coupling analysis to guide AAV capsid engineering, suggesting that conservative mutations informed by evolutionary data can improve AAV stability and efficacy.

Abstract

Adeno-associated virus (AAV) has emerged as a leading platform for gene therapy. However, to unlock the full potential, their manufacturing yields, stability, and efficacy must all be improved. Rational design is limited by poor predictability and the potential impact of mutations on multiple important vector properties. Directed evolution requires little knowledge or predictability, but requires large libraries, and lacks appropriate selection methods to ensure that all properties needed for successful translation are achieved. Here we bring semi-rational design to AAV capsid engineering, combining co-evolutionary coupling and consensus-based design. We designed 110 mutants at sites with different degrees of coupling and mutated them either back to consensus or with various residue similarities according to BLOSUM62. Seven were selected based on their yields and transduction efficiencies before and after heat treatment. Our results demonstrate that mutations at sites within coupled networks exhibited the highest success rates. The BLOSUM62 selection strategy and consensus design approaches had similar success rates. K-means clustering of mutants further revealed that five of the successful mutants clustered in regions with moderate coupling scores and positive BLOSUM62 values. This study highlights the potential of using evolutionary coupling analysis to guide AAV capsid engineering, suggesting that conservative mutations informed by evolutionary data can improve AAV stability and efficacy.

Read PDF

Similar papers

2026

Site-Specific Chemical Conjugation of Recombinant Proteins onto the AAV Capsid.

This platform provides a powerful approach for engineering next-generation AAV vectors with customizable targeting profiles for diverse therapeutic applications and preserves AAV integrity and infectivity, and enables programmable retargeting of AAV tropism toward disease-relevant receptors.

Quan Pham, Jake Glicksman, Abhishek Chatterjee · 0 citations
Open access Aug 2026

Modified Plasmids and Inverted Terminal Repeats Enhance Adeno-Associated Virus Production and Performance

A 140% increase in pHelper plasmid production is reported, while the most successful ITR variant increased pTransgene plasmid yields by 57% and transgene expression by 28%, without reducing rAAV yields or transduction efficiency.

Nicholas Donohue, Alexandra Bogdanovic, James Conheady et al. · 0 citations
#gene editing Review Open access Aug 2026

Navigating Quality, Safety, and Analytical Testing Frameworks for Viral Vector–Based Gene Editing Therapies

This article aims to provide a working framework for verifying the potency, genomic integrity, and clinical safety of vector-based gene therapies—one intended to be useful both to laboratories developing these products and to those responsible for regulating them.

Yusra A. Radeef, Z. Abdullah, E. F. A. Awadh · 0 citations
Open access Jul 2026

A novel adeno-associated viral vector derived from human spleen isolate AAV.hu.S17

This study generated a novel recombinant AAV vector rAAV.hu.hu.S17, derived from the human spleen isolate AAV.hu.S17, and systematically evaluated its capsid features, in vitro transduction, and in vivo tissue tropism.

Wenyan Guo, Jiawen Sun, Fei Wang et al. · 0 citations
Open access Jul 2026

Genome-Wide Characterization of Recombinant AAV6 Vector Integration in Human CD34+ Cells.

The data support the genomic safety of rAAV6 and its applicability to hematological gene therapy and functional enrichment analysis indicated associations with general cellular and structural processes, without enrichment in oncogenic pathways.

H. Lee, Nayoung Park, In-Byung Park et al. · 0 citations
Review Open access Jul 2026

Standardisation in the Analytical Characterization of Adeno-Associated Virus (AAV) Vectors.

Establishing robust, serotype-specific AAV RSMs and harmonised standard operating protocols (SOPs) are essential for advancing AAV gene therapy and ensuring accuracy, reproducibility, and safety across research, development, and clinical manufacturing.

Saleheen Khan, Nathalie Van den Berghe, Els Henckaerts · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.